Zacks: Analysts Expect Celsion Co. (CLSN) Will Post Earnings of -$0.31 Per Share

Equities analysts expect Celsion Co. (NASDAQ:CLSN) to post earnings of ($0.31) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Celsion’s earnings, with estimates ranging from ($0.32) to ($0.29). Celsion posted earnings of ($1.96) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 84.2%. The firm is scheduled to announce its next earnings report on Thursday, March 15th.

According to Zacks, analysts expect that Celsion will report full-year earnings of ($2.46) per share for the current fiscal year. For the next year, analysts anticipate that the business will report earnings of ($1.15) per share, with EPS estimates ranging from ($1.21) to ($1.08). Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for Celsion.

Several equities analysts have recently weighed in on the company. ValuEngine cut Celsion from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Oppenheimer assumed coverage on Celsion in a research report on Tuesday, November 21st. They issued an “outperform” rating and a $9.00 price target for the company. Finally, Zacks Investment Research upgraded Celsion from a “sell” rating to a “hold” rating in a research report on Tuesday, December 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $11.90.

Shares of Celsion (NASDAQ CLSN) traded down $0.06 during midday trading on Tuesday, hitting $2.20. The stock had a trading volume of 216,946 shares, compared to its average volume of 317,036. The stock has a market capitalization of $39.01, a PE ratio of -0.38 and a beta of 1.82. Celsion has a one year low of $1.24 and a one year high of $6.06.

An institutional investor recently bought a new position in Celsion stock. Virtu Financial LLC purchased a new stake in Celsion Co. (NASDAQ:CLSN) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 42,018 shares of the biotechnology company’s stock, valued at approximately $113,000. Virtu Financial LLC owned approximately 0.24% of Celsion as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 3.63% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at

Celsion Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Get a free copy of the Zacks research report on Celsion (CLSN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with's FREE daily email newsletter.

Leave a Reply